MA42935B1 - Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations - Google Patents
Anticorps bispécifiques anti-cd3 optimisés et leurs utilisationsInfo
- Publication number
- MA42935B1 MA42935B1 MA42935A MA42935A MA42935B1 MA 42935 B1 MA42935 B1 MA 42935B1 MA 42935 A MA42935 A MA 42935A MA 42935 A MA42935 A MA 42935A MA 42935 B1 MA42935 B1 MA 42935B1
- Authority
- MA
- Morocco
- Prior art keywords
- antigen
- antibodies
- binding
- human
- cells
- Prior art date
Links
- 239000000427 antigen Substances 0.000 abstract 7
- 102000036639 antigens Human genes 0.000 abstract 7
- 108091007433 antigens Proteins 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 2
- 241000282412 Homo Species 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000099 in vitro assay Methods 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des anticorps qui se lient à cd3 avec peu ou pas d'affinité de liaison détectable et leurs procédés d'utilisation. Selon certains modes de réalisation, les anticorps de l'invention se lient au cd3 humain avec une faible affinité et induisent la prolifération de lymphocytes t humains, et par conséquent induisent la destruction, à travers les lymphocytes t, de cellules tumorales avec une grande efficacité. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à l'antigène bispécifique comprenant un premier domaine de liaison à l'antigène qui se lie spécifiquement au cd3 humain avec peu ou pas d'affinité de liaison détectable dans un essai in vitro, et une seconde molécule de liaison à l'antigène qui se lie spécifiquement à un antigène associé à une tumeur chez l'homme. Dans certains modes de réalisation, les molécules de liaison à l'antigène bispécifique selon la présente invention sont capables d'inhiber la croissance de tumeurs exprimant l'antigène cible, par exemple psma. Les anticorps et les molécules de liaison à l'antigène bispécifique de l'invention sont utiles pour le traitement de maladies et de troubles dans lesquels une réponse immunitaire ciblée positivement régulée ou induite est souhaitée et/ou thérapeutiquement bénéfique. Par exemple, les anticorps de l'invention sont utiles pour le traitement de divers cancers ou d'autres maladies où l'immunothérapie, c'est-à-dire. L'immunomodulation de cellule effectrice est garantie.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562222605P | 2015-09-23 | 2015-09-23 | |
| PCT/US2016/053525 WO2017053856A1 (fr) | 2015-09-23 | 2016-09-23 | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA42935A MA42935A (fr) | 2018-08-01 |
| MA42935B1 true MA42935B1 (fr) | 2022-02-28 |
Family
ID=57130447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA42935A MA42935B1 (fr) | 2015-09-23 | 2016-09-23 | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20180355038A1 (fr) |
| EP (1) | EP3353212B1 (fr) |
| JP (3) | JP7023231B2 (fr) |
| KR (1) | KR102777500B1 (fr) |
| CN (1) | CN108290951B (fr) |
| AU (1) | AU2016325630B2 (fr) |
| BR (1) | BR112018005445A2 (fr) |
| CA (1) | CA2999385A1 (fr) |
| CY (1) | CY1124944T1 (fr) |
| DK (1) | DK3353212T3 (fr) |
| EA (1) | EA201890785A1 (fr) |
| ES (1) | ES2901133T3 (fr) |
| HR (1) | HRP20220133T8 (fr) |
| HU (1) | HUE057683T2 (fr) |
| IL (1) | IL258036B (fr) |
| LT (1) | LT3353212T (fr) |
| MA (1) | MA42935B1 (fr) |
| MD (1) | MD3353212T2 (fr) |
| MX (1) | MX2018003403A (fr) |
| MY (1) | MY195059A (fr) |
| PL (1) | PL3353212T3 (fr) |
| PT (1) | PT3353212T (fr) |
| RS (1) | RS62859B1 (fr) |
| SI (1) | SI3353212T1 (fr) |
| SM (1) | SMT202200050T1 (fr) |
| TW (2) | TWI783914B (fr) |
| WO (1) | WO2017053856A1 (fr) |
| ZA (1) | ZA201801673B (fr) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| PT3699198T (pt) | 2014-11-17 | 2025-04-29 | Regeneron Pharma | Métodos para o tratamento de tumores usando anticorpos biespecíficos cd3xcd20 |
| EP3277725B1 (fr) | 2015-03-30 | 2020-11-25 | Regeneron Pharmaceuticals, Inc. | Régions constantes de chaînes lourdes présentant une liaison réduite aux récepteurs fc gamma |
| EP3795679A1 (fr) | 2015-05-28 | 2021-03-24 | Genentech, Inc. | Essai à base de cellules pour détecter des anti-homodimères cd3 |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| PT3353212T (pt) * | 2015-09-23 | 2022-01-05 | Regeneron Pharma | Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações |
| AU2017253241B2 (en) | 2016-04-20 | 2024-07-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| KR20180134894A (ko) | 2016-04-20 | 2018-12-19 | 리제너론 파마슈티칼스 인코포레이티드 | 발현 강화 유전자좌의 사용에 기초하여 항체를 만들기 위한 조성물 및 방법 |
| SMT202200359T1 (it) | 2016-09-23 | 2022-11-18 | Regeneron Pharma | Anticorpi anti-muc16 (mucina 16) |
| KR20250016462A (ko) | 2016-12-21 | 2025-02-03 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
| EP3409322A1 (fr) | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Procédés de traitement |
| JP2020525432A (ja) * | 2017-06-22 | 2020-08-27 | ディベロップメント センター フォー バイオテクノロジーＤｅｖｅｌｏｐｍｅｎｔ Ｃｅｎｔｅｒ Ｆｏｒ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ | 非対称ヘテロ二量体ＦＣ−ＳＣＦＶ融合抗ＧＬＯＢＯ Ｈおよび抗ＣＤ３二重特異的抗体およびがん療法（ｃａｎｅｒ ｔｈｅｒａｐｙ）におけるその使用 |
| FI3665198T3 (fi) * | 2017-08-09 | 2025-04-25 | Merus Nv | EGFR:ää ja cMET:tä sitovia vasta-aineita |
| EA039842B1 (ru) * | 2017-09-14 | 2022-03-18 | Ридженерон Фармасьютикалз, Инк. | Биспецифичные анти-muc16-cd3 антитела и конъюгаты анти-muc16-лекарственное средство |
| JP2021500865A (ja) * | 2017-09-29 | 2021-01-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | スタフィロコッカス（Ｓｔａｐｈｓｙｌｏｃｏｃｃｕｓ）標的抗原および補体成分に結合する二重特異性抗原結合分子ならびにその使用 |
| CN111886250A (zh) * | 2017-12-27 | 2020-11-03 | 特尼奥生物股份有限公司 | CD3-δ/ε异二聚体特异性抗体 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| KR20250156829A (ko) | 2018-06-21 | 2025-11-03 | 리제너론 파아마슈티컬스, 인크. | 이중특이적 항-psma x 항-cd28 항체 및 이의 용도 |
| CN112584859A (zh) | 2018-07-02 | 2021-03-30 | 美国安进公司 | 抗steap1抗原结合蛋白 |
| TWI838389B (zh) * | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| RS65384B1 (sr) | 2018-07-19 | 2024-04-30 | Regeneron Pharma | Himerni antigenski receptori specifični za bcma i njihove upotrebe |
| AU2019325565B2 (en) | 2018-08-23 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Anti-Fc epsilon-R1 alpha (FceR1a) antibodies, bispecific antigen-binding molecules that bind FceR1a and CD3, and uses thereof |
| RS66543B1 (sr) | 2018-08-31 | 2025-03-31 | Regeneron Pharma | Strategija doziranja koja ublažava sindrom oslobađanja citokina za cd3/cd20 bispecifična antitela |
| TW202506736A (zh) | 2018-10-11 | 2025-02-16 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| WO2020076970A1 (fr) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Anticorps b7h3 à domaine unique et compositions thérapeutiques associées |
| WO2020077257A1 (fr) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Anticorps pd-1 à domaine unique et compositions thérapeutiques associées |
| CA3115089A1 (fr) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Anticorps a domaine unique dll3 et compositions therapeutiques |
| CN111138542B (zh) * | 2018-11-01 | 2022-09-23 | 山东新时代药业有限公司 | 双特异性抗体及其用途 |
| KR20210099614A (ko) * | 2018-12-04 | 2021-08-12 | 노파르티스 아게 | Cd3에 대한 결합 분자 및 이의 용도 |
| CN112955471B (zh) * | 2018-12-07 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Cd3抗体及其药物用途 |
| CA3123420A1 (fr) | 2018-12-19 | 2020-06-25 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-muc16 x anti-cd28 bispecifiques et leurs utilisations |
| AU2019405747A1 (en) | 2018-12-19 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof |
| KR20210142659A (ko) | 2019-03-22 | 2021-11-25 | 리제너론 파아마슈티컬스, 인크. | Egfr×cd28 다중특이성 항체 |
| CN113874398B (zh) | 2019-05-21 | 2025-08-01 | 诺华股份有限公司 | Cd19结合分子及其用途 |
| WO2020257604A1 (fr) * | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Utilisation de molécules de liaison à l'antigène bispécifiques qui se lient à muc16 et cd3 en combinaison avec une co-stimulation de 4-1bb |
| KR20220024594A (ko) * | 2019-06-21 | 2022-03-03 | 리제너론 파마슈티칼스 인코포레이티드 | Psma 및 cd3에 결합하는 이중 특이적 항원 결합 분자와 4-1bb 공동 자극의 병용 |
| CA3143519A1 (fr) * | 2019-06-26 | 2020-12-30 | Volker Schellenberger | Fragments de liaison a l'antigene cd3 et compositions les comprenant |
| TWI889320B (zh) | 2019-07-05 | 2025-07-01 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| BR112022002012A2 (pt) | 2019-08-15 | 2022-06-07 | Regeneron Pharma | Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma |
| CN110551222B (zh) * | 2019-08-27 | 2023-06-06 | 重庆市畜牧科学院 | 一种新型双功能抗体及其用途 |
| US20220372155A1 (en) * | 2019-10-23 | 2022-11-24 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| EP4069373A1 (fr) | 2019-12-06 | 2022-10-12 | Regeneron Pharmaceuticals, Inc. | Méthodes de traitement du myélome multiple avec des anticorps bispecifiques anti-bcma x anti-cd3 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| JP2023532807A (ja) | 2020-07-08 | 2023-07-31 | ラヴァ・セラピューティクス・エヌ・ヴイ | Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体 |
| EP4214233A1 (fr) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Méthodes d'administration de doses thérapeutiques de molécules bispécifiques activant les lymphocytes t pour le traitement du cancer |
| FI4284512T3 (fi) | 2021-01-28 | 2025-05-22 | Regeneron Pharma | Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi |
| WO2022192895A1 (fr) * | 2021-03-10 | 2022-09-15 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Compositions et méthodes permettant de réduire la toxicité de lymphocytes t thérapeutiques |
| IL308257A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Antigen binding proteins that uniquely bind PRAME |
| US20250019439A1 (en) * | 2021-11-24 | 2025-01-16 | Adimab, Llc | Anti-idiotype antibodies |
| JP2025510232A (ja) | 2022-03-29 | 2025-04-14 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | Ｉｌｔ３及びｃｄ３結合剤及びその使用方法 |
| CA3247475A1 (fr) | 2022-04-11 | 2023-10-19 | Regeneron Pharmaceuticals, Inc. | Compositions et méthodes permettant la destruction de cellule tumorale universelle |
| CN114685675B (zh) * | 2022-04-27 | 2023-02-03 | 深圳市汉科生物工程有限公司 | 双特异性抗体及其在治疗癌症中的用途 |
| WO2024012513A1 (fr) * | 2022-07-13 | 2024-01-18 | Hansoh Bio Llc | Anticorps, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique associée |
| WO2024077044A1 (fr) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Polythérapies comprenant des thérapies de redirection de lymphocytes t et des anticorps agonistes anti-il-2r ou des fragments de ceux-ci |
| CN120282798A (zh) | 2022-10-10 | 2025-07-08 | 瑞泽恩制药公司 | 用于降低需要实体器官移植的受试者中的同种抗体水平的方法 |
| WO2024088987A1 (fr) | 2022-10-26 | 2024-05-02 | F. Hoffmann-La Roche Ag | Polythérapie pour le traitement du cancer |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
| KR20250156813A (ko) | 2023-03-13 | 2025-11-03 | 리제너론 파아마슈티컬스, 인크. | 이중특이성 항-CD22 x 항-CD28 분자를 이용한 암 치료 방법 |
| AU2024297594A1 (en) | 2023-07-10 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1xcd28 antibodies and methods of use thereof |
| US20250043017A1 (en) | 2023-07-10 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF |
| WO2025080533A1 (fr) * | 2023-10-09 | 2025-04-17 | Janux Therapeutics, Inc. | Anticorps ciblant steap-1 et cd3, leurs utilisations |
| WO2025131075A1 (fr) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | Anticorps multispécifiques anti-cd3 et anti-cd3, et utilisation |
| WO2025199278A2 (fr) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Molécules de liaison à l'antigène multispécifiques masquées avec agents de liaison clivables |
| WO2025199352A2 (fr) | 2024-03-20 | 2025-09-25 | Juno Therapeutics, Inc. | Anticorps spécifiques du membre 2 de la famille des transporteurs de solutés 34 (slc34a2) |
| WO2025217101A2 (fr) | 2024-04-09 | 2025-10-16 | Amgen Inc. | Anticorps agonistes à chaîne lourde anti-il-2rbg |
| WO2025240670A2 (fr) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anticorps anti-pd-1 et molécules de liaison associées et procédés et utilisations associés |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| CA2461631A1 (fr) * | 2001-09-28 | 2003-04-03 | Elusys Therapeutics, Inc. | Methodes et compositions de prevention, de diagnostic, et de traitement du cancer au moyen de molecules bispecifiques |
| US7820166B2 (en) | 2002-10-11 | 2010-10-26 | Micromet Ag | Potent T cell modulating molecules |
| AU2004242845B2 (en) | 2003-05-31 | 2011-06-02 | Amgen Research (Munich) Gmbh | Human-anti-human CD3 binding molecules |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CN104072614B (zh) * | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2010054212A1 (fr) * | 2008-11-06 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Mise au point d’anticorps à immunogénicité réduite et méthodes de fabrication associées |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US20120316071A1 (en) | 2009-11-04 | 2012-12-13 | Vaughn Smider | Methods for affinity maturation-based antibody optimization |
| PL2501817T5 (pl) | 2010-02-08 | 2021-08-16 | Regeneron Pharmaceuticals, Inc. | Mysz o wspólnym łańcuchu lekkim |
| DK2603523T3 (en) * | 2010-08-12 | 2016-03-21 | Lilly Co Eli | ANTI-N3pGlu-AMYLOIDBETAPEPTIDANTISTOFFER AND USES THEREOF |
| US20130058936A1 (en) * | 2011-08-23 | 2013-03-07 | Peter Bruenker | Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use |
| WO2013157105A1 (fr) * | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | Anticorps humain spécifique de mucine 5ac et son utilisation |
| WO2013184761A1 (fr) * | 2012-06-05 | 2013-12-12 | Regeneron Pharmaceuticals, Inc. | Procédés pour préparer des anticorps bispécifiques entièrement humains en utilisant une chaîne légère commune |
| DE102012214441B4 (de) * | 2012-08-14 | 2020-08-06 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Messverfahren |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| PT2900694T (pt) * | 2012-09-27 | 2018-11-13 | Merus Nv | Anticorpos de igg biespecíficos como ativadores de células t |
| MX2015003616A (es) * | 2012-10-08 | 2015-06-05 | Roche Glycart Ag | Anticuerpos sin fc que comprenden dos fragmentos fab y metodos de uso. |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| KR20160099087A (ko) * | 2013-12-20 | 2016-08-19 | 에프. 호프만-라 로슈 아게 | 이중특이성 her2 항체 및 사용 방법 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20160154B1 (ar) * | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| PT3353212T (pt) * | 2015-09-23 | 2022-01-05 | Regeneron Pharma | Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações |
| SMT202200359T1 (it) * | 2016-09-23 | 2022-11-18 | Regeneron Pharma | Anticorpi anti-muc16 (mucina 16) |
| JP7078609B2 (ja) * | 2016-09-23 | 2022-05-31 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓｔｅａｐ２抗体、抗体－薬物複合体、およびｓｔｅａｐ２とｃｄ３を結合する二重特異性抗原結合分子、ならびにそれらの使用 |
| BR112022002012A2 (pt) * | 2019-08-15 | 2022-06-07 | Regeneron Pharma | Moléculas multispecíficas de ligação a antígeno para células-alvo e usos das mesma |
-
2016
- 2016-09-23 PT PT167812361T patent/PT3353212T/pt unknown
- 2016-09-23 WO PCT/US2016/053525 patent/WO2017053856A1/fr not_active Ceased
- 2016-09-23 BR BR112018005445A patent/BR112018005445A2/pt active Search and Examination
- 2016-09-23 KR KR1020187011246A patent/KR102777500B1/ko active Active
- 2016-09-23 MY MYPI2018700990A patent/MY195059A/en unknown
- 2016-09-23 MX MX2018003403A patent/MX2018003403A/es unknown
- 2016-09-23 JP JP2018534519A patent/JP7023231B2/ja active Active
- 2016-09-23 TW TW105130880A patent/TWI783914B/zh active
- 2016-09-23 MD MDE20180740T patent/MD3353212T2/ro unknown
- 2016-09-23 SM SM20220050T patent/SMT202200050T1/it unknown
- 2016-09-23 RS RS20220089A patent/RS62859B1/sr unknown
- 2016-09-23 AU AU2016325630A patent/AU2016325630B2/en active Active
- 2016-09-23 HR HRP20220133TT patent/HRP20220133T8/hr unknown
- 2016-09-23 PL PL16781236T patent/PL3353212T3/pl unknown
- 2016-09-23 ES ES16781236T patent/ES2901133T3/es active Active
- 2016-09-23 HU HUE16781236A patent/HUE057683T2/hu unknown
- 2016-09-23 EP EP16781236.1A patent/EP3353212B1/fr active Active
- 2016-09-23 EA EA201890785A patent/EA201890785A1/ru unknown
- 2016-09-23 US US15/780,504 patent/US20180355038A1/en not_active Abandoned
- 2016-09-23 CA CA2999385A patent/CA2999385A1/fr active Pending
- 2016-09-23 DK DK16781236.1T patent/DK3353212T3/da active
- 2016-09-23 CN CN201680068487.4A patent/CN108290951B/zh active Active
- 2016-09-23 LT LTEPPCT/US2016/053525T patent/LT3353212T/lt unknown
- 2016-09-23 TW TW111122347A patent/TWI784917B/zh active
- 2016-09-23 MA MA42935A patent/MA42935B1/fr unknown
- 2016-09-23 SI SI201631414T patent/SI3353212T1/sl unknown
- 2016-09-23 IL IL258036A patent/IL258036B/en unknown
-
2018
- 2018-03-12 ZA ZA2018/01673A patent/ZA201801673B/en unknown
-
2021
- 2021-03-19 US US17/207,462 patent/US20210253701A1/en active Pending
- 2021-12-27 JP JP2021211788A patent/JP7695877B2/ja active Active
-
2022
- 2022-02-02 CY CY20221100087T patent/CY1124944T1/el unknown
-
2023
- 2023-08-10 JP JP2023130597A patent/JP2023154021A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA42935B1 (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| MA53168B1 (fr) | Anticorps anti-bcma x anti-cd3 bispécifiques et leurs utilisations | |
| JOP20160154B1 (ar) | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها | |
| ZA202308021B (en) | Anti-ctla4 antibodies and methods of making and using the same | |
| MX2020013804A (es) | Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos. | |
| EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
| PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
| EA201990781A9 (ru) | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| WO2020077276A3 (fr) | Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci | |
| EA202091888A1 (ru) | Вариабельные домены антител, нацеленные на рецептор nkg2d | |
| WO2022081718A8 (fr) | Anticorps anti-récepteur de chimiokine c-c 8 (ccr8) et leurs procédés d'utilisation | |
| EA202090372A1 (ru) | Универсальные соединения авт и их применение | |
| MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
| JP2018052979A5 (fr) | ||
| JP2017537972A5 (fr) | ||
| MA43717B1 (fr) | Anticorps anti-tnf alpha et fragments fonctionnels de ceux-ci | |
| Douka et al. | Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy | |
| CR20230245A (es) | Moléculas de unión a gucy2c y sus usos | |
| Aschmoneit et al. | Fc-comprising scDb-based trivalent, bispecific T-cell engagers for selective killing of HER3-expressing cancer cells independent of cytokine release | |
| WO2023129819A3 (fr) | Anticorps à haute affinité à domaine unique et leurs méthodes d'utilisation | |
| MA42523B1 (fr) | Anticorps anti-psma, molécules liant l'antigène bispécifiques qui se lient à psma et à cd3 et leurs utilisations | |
| EA202190314A1 (ru) | Биспецифические анти-bcma x анти-cd3 антитела и способы их применения | |
| MA37998B2 (fr) | Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations | |
| MA47976B1 (fr) | Anticorps dirigés contre trem2 et leur utilisation | |
| Paliwal et al. | CAR T-Cell Therapy: Hope and Healing in the Battle Against Cancer |